Company: GHRS
Filing Date: 2025-07-29
Form Type: 20-F/A
Source: 0001140361-25-027850
Chunk: 14

Company: GH Research PLC
Filing Date: 2025-07-29
Form: 20-F/A
Chunk 14
---
002 product candidates including the medical devices required to deliver these therapies for our initial and any additional 
 indications, and other product candidates we may develop and pursue;                                                                                                                                                                    |

| • | the duration of the clinical hold imposed by the FDA on the study we proposed in our IND for GH001, including the progression of, and associated costs from, any nonclinical programs and any other work necessary to lift the clinical hold, 
 as well as discussions with the FDA and the outcomes and resolution of such discussions;                                                                                                                                                      |

| • | the number of future product candidates that we may pursue and their development requirements; |

| • | the number of jurisdictions in which we plan to seek regulatory approvals; |

| • | if approved, the costs of commercialization activities for GH001 and GH002 for any approved indications, or any other product candidate that receives regulatory approval to the extent such costs are not the responsibility of any future 
 collaborators, including the costs and timing of establishing product sales, marketing, distribution, and manufacturing capabilities;                                                                                                       |

| • | subject to receipt of regulatory approval, revenue, if any, received from commercial sales of GH001 and GH002 and the respective medical devices for any approved indications or any other product candidates; |

| • | if approved, the establishment and maintenance of coverage and adequate reimbursement from third-party payors for GH001, GH002 or any other product candidates; |

| • | the extent to which we may in-license or acquire rights to other products, product candidates, medical devices or technologies; |

| • | our headcount growth and associated costs as we expand our research and development, increase our office space, and establish a commercial infrastructure; |

| • | the costs of preparing, filing and prosecuting patent applications and maintaining and protecting our intellectual property rights, including enforcing and defending intellectual property-related claims; |

5 Table of Contents

| • | the effect of competing product and market developments; and |

| • | the ongoing costs of operating as a public company. |

We cannot be certain that additional funding will be available on acceptable terms, or at all. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. Any of our current or future license agreements may be terminated if we are unable to meet the payment or other obligations under the agreements. Raising additional capital may cause dilution to